CD33 and acute myeloid leukemia: In 2017, Mylotarg® was reevaluated and received renewed regulatory approval for the treatment of CD33-positive newly diagnosed AML in adult patients, with the single administration dose reduced from the original 9 mg/m2 (used in 2000) to 3 mg/m2 (104).